AIM
TBPH icon

Aigen Investment Management’s Theravance Biopharma TBPH Stock Holding History

Aigen Investment Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-23,719
Closed -$257K – 956
2023
Q1 		$257K Buy
+23,719
New +$251K 0.04% 465
2020
Q4 		– Sell
-4,663
Closed -$69K – 1039
2020
Q3 		$69K Sell
4,663
-8,766
-65% -$164K 0.01% 754
2020
Q2 		$282K Buy
13,429
+3,477
+35% +$89.3K 0.04% 630
2020
Q1 		$230K Buy
9,952
+9,933
+52,279% +$249K 0.03% 664
2019
Q4 		$0 Buy
+19
New +$369 ﹤0.01% 1147

Other funds holding TBPH

WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aigen Investment Management's TBPH Position: Q2 2023 in Review

Aigen Investment Management sold out of Theravance Biopharma (TBPH) in Q2 2023, closing a stake of 23,719 shares — an estimated $257K sold.

Aigen Investment Management first reported a position in TBPH in Q4 2019 and held it in 5 quarters. The position peaked at $282K in Q2 2020. 119 funds tracked by Wall St. Rank hold TBPH as of Q2 2023.

  • Aigen Investment Management reported no remaining Theravance Biopharma position as of Q2 2023 after selling out during the quarter.
  • Aigen Investment Management sold 23,719 Theravance Biopharma shares in Q2 2023, an estimated $257K.
  • Aigen Investment Management first reported a position in Theravance Biopharma in Q4 2019 and held it in 5 quarters.
  • Aigen Investment Management's Theravance Biopharma position peaked at $282K in Q2 2020.
  • 119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2023.

Based on Aigen Investment Management's 13F filing for Q2 2023, filed 14 Aug 2023.